NCT00666354

Dose Response and Safety Study of Topical Methotrexate for the Treatment of Fingernail Psoriasis

Phase IIB Dose Response and Safety Study of Topical Formulations of Methotrexate (MQX-5902, MQX-5904 and MQX-5906) in the Treatment of Fingernail Psoriasis

• Status: Unknown
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 83 (estimated)
• Sponsor: MediQuest Therapeutics · Industry
• Sex: All
• Age: 18 Years – 75 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this clinical study is to compare the efficacy and safety of three concentrations of topical methotrexate for the treatment of fingernail psoriasis.

Detailed description

The purpose of this clinical study is to compare, in a controlled fashion, the response to three concentrations of methotrexate in novel topical formulations in the treatment of subjects with psoriasis of the fingernails. Such a determination will be used as the basis for evidence of efficacy and safety of these formulations as a therapeutic treatment for fingernail psoriasis.

Conditions

• Fingernail Psoriasis

Interventions

Type	Name	Description
DRUG	Methotrexate	0.01 gram of topical amphimatrix containing 0.05% methotrexate per affected nail and adjacent skin folds applied daily for three months.
DRUG	Methotrexate	0.01 gram of topical amphimatrix containing 0.25% methotrexate per affected nail and adjacent skin folds applied daily for three months.
DRUG	Methotrexate	0.01 gram of topical amphimatrix containing 1.0% methotrexate per affected nail and adjacent skin folds applied daily for three months.

Timeline

• Start date: 2007-10-01
• Primary completion: 2008-09-01
• Completion: 2009-01-01
• First posted: 2008-04-24
• Last updated: 2009-02-10

Locations

7 sites across 1 country: United Kingdom